---
figid: PMC2360544__95-6603223f2
figtitle: Novel therapeutic targets and proposed mechanisms of androgen resistance
  (text in red) in hormone refractory prostate cancer
organisms:
- NA
pmcid: PMC2360544
filename: 95-6603223f2.jpg
figlink: /pmc/articles/PMC2360544/figure/fig2/
number: F2
caption: 'Novel therapeutic targets and proposed mechanisms of androgen resistance
  (text in red) in hormone refractory prostate cancer. (1) Hypersensitive Pathway:
  AR amplification, increased AR expression or alterations in corepressor/coactivator
  function. (2) Versatile receptor: mutations in the ligand-binding domain of the
  AR permitting nonandrogenic ligand binding. (3) Alternative routes: utilisation
  of AR machinery by alternative pathways, that is, PI3K/Akt. (4) Bypass pathways:
  bypassing of the AR and its cellular machinery entirely, that is, upregulation of
  the antiapoptotic protein Bcl-2. Therapeutic targets include: the adrenal steroid
  synthesis pathway, AR signalling, growth factor receptors (GFR), PTEN (phosphatase
  and tensin homolog) and PI3K (phosphatidylinositide 3-OH kinase) signalling, angiogenesis
  and apoptosis. HSP90 denotes heat shock protein 90; PIP2 phosphatidylinositol-4,5-
  bisphosphate; PIP3 phosphatidylinositol-3,4,5- triphosphate; Akt protein kinase
  B; mTOR mammalian target of rapamycin; oncogenes Ras, Raf, Mek, Erk; Bcl-2 antiapoptotic
  protein; APAF1 apoptotic peptidase activating factor 1; IAP inhibitor of apoptosis
  family (of which survivin is a member). Solid lines indicate promotion. Broken lines
  indicate inhibition.'
papertitle: Improving the outcome of patients with castration-resistant prostate cancer
  through rational drug development.
reftext: G Attard, et al. Br J Cancer. 2006 Oct 9;95(7):767-774.
year: '2006'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.7993891
figid_alias: PMC2360544__F2
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC2360544__F2
ndex: a454e98e-df2a-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2360544__95-6603223f2.html
  '@type': Dataset
  description: 'Novel therapeutic targets and proposed mechanisms of androgen resistance
    (text in red) in hormone refractory prostate cancer. (1) Hypersensitive Pathway:
    AR amplification, increased AR expression or alterations in corepressor/coactivator
    function. (2) Versatile receptor: mutations in the ligand-binding domain of the
    AR permitting nonandrogenic ligand binding. (3) Alternative routes: utilisation
    of AR machinery by alternative pathways, that is, PI3K/Akt. (4) Bypass pathways:
    bypassing of the AR and its cellular machinery entirely, that is, upregulation
    of the antiapoptotic protein Bcl-2. Therapeutic targets include: the adrenal steroid
    synthesis pathway, AR signalling, growth factor receptors (GFR), PTEN (phosphatase
    and tensin homolog) and PI3K (phosphatidylinositide 3-OH kinase) signalling, angiogenesis
    and apoptosis. HSP90 denotes heat shock protein 90; PIP2 phosphatidylinositol-4,5-
    bisphosphate; PIP3 phosphatidylinositol-3,4,5- triphosphate; Akt protein kinase
    B; mTOR mammalian target of rapamycin; oncogenes Ras, Raf, Mek, Erk; Bcl-2 antiapoptotic
    protein; APAF1 apoptotic peptidase activating factor 1; IAP inhibitor of apoptosis
    family (of which survivin is a member). Solid lines indicate promotion. Broken
    lines indicate inhibition.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ras
  - Ras64B
  - Ras85D
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - ar
  - Akt
  - Raf
  - Adar
  - bo
  - an
  - Mtor
  - Tor
  - Dsor1
  - Mtk
  - Erk7
  - rl
  - Psa
  - Ets21C
  - Ets65A
  - pnt
  - Ets96B
  - Ets97D
  - Ets98B
  - CRCP
  - CYTL1
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AR
  - AKT1
  - AKT2
  - AKT3
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - ADAR
  - AN
  - MTOR
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - KLK3
  - PLAG1
  - PROS1
  - NPEPPS
  - PSAT1
  - ETS1
  - ETS2
  - TMPRSS2
  - androgens
  - Testosterone
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
